File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Successful ovulation in plasminogen-deficient mice treated with the broad-spectrum matrix metalloproteinase inhibitor galardin

TitleSuccessful ovulation in plasminogen-deficient mice treated with the broad-spectrum matrix metalloproteinase inhibitor galardin
Authors
KeywordsMice
Matrix metalloproteinases
Ovulation
Plasminogen activators
Issue Date2006
Citation
Developmental Biology, 2006, v. 295, n. 2, p. 615-622 How to Cite?
AbstractMany studies have suggested the hypothesis that the plasminogen activator (PA) system and the matrix metalloproteinase (MMP) system, either separately or in combination, may provide the proteolytic activity that is required for rupture of the follicular wall at the time of ovulation. Our recent studies on ovulation in plasminogen (plg)-deficient mice have, however, shown that plasmin is not required for normal ovulation, leading us to the hypothesis that MMPs may be a more important source of proteolysis for this process. To investigate the role of MMPs and also the possibility of a functional overlap or synergy between the MMP and PA systems during ovulation, we have studied ovulation efficiency in wild-type and plg-deficient mice treated with the broad-spectrum MMP inhibitor galardin. We found that in both wild-type mice and heterozygous plg-deficient (plg+/-) mice that had been treated with galardin prior to ovulation, there was a mild (18-20%) reduction in ovulation efficiency. Surprisingly, galardin treatment of plg-deficient (plg-/-) mice only caused an additional 14% reduction in ovulation efficiency as compared to vehicle-treated plg-/- mice. Our data therefore suggest that although MMPs may play a role in degradation of the follicular wall, they may not be obligatory for ovulation. In contrast to previous studies on tissue remodeling during wound healing and placental development, we have demonstrated that there is no obvious functional overlap or synergy between the PA and MMP systems, which has previously been thought to be essential for the ovulatory process. © 2006 Elsevier Inc. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/265772
ISSN
2017 Impact Factor: 3.262
2015 SCImago Journal Rankings: 2.554
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLiu, Kui-
dc.contributor.authorWahlberg, Patrik-
dc.contributor.authorLeonardsson, Göran-
dc.contributor.authorHägglund, Anna Carin-
dc.contributor.authorNy, Annelii-
dc.contributor.authorBodén, Ida-
dc.contributor.authorWibom, Carin-
dc.contributor.authorLund, Leif R.-
dc.contributor.authorNy, Tor-
dc.date.accessioned2018-12-03T01:21:38Z-
dc.date.available2018-12-03T01:21:38Z-
dc.date.issued2006-
dc.identifier.citationDevelopmental Biology, 2006, v. 295, n. 2, p. 615-622-
dc.identifier.issn0012-1606-
dc.identifier.urihttp://hdl.handle.net/10722/265772-
dc.description.abstractMany studies have suggested the hypothesis that the plasminogen activator (PA) system and the matrix metalloproteinase (MMP) system, either separately or in combination, may provide the proteolytic activity that is required for rupture of the follicular wall at the time of ovulation. Our recent studies on ovulation in plasminogen (plg)-deficient mice have, however, shown that plasmin is not required for normal ovulation, leading us to the hypothesis that MMPs may be a more important source of proteolysis for this process. To investigate the role of MMPs and also the possibility of a functional overlap or synergy between the MMP and PA systems during ovulation, we have studied ovulation efficiency in wild-type and plg-deficient mice treated with the broad-spectrum MMP inhibitor galardin. We found that in both wild-type mice and heterozygous plg-deficient (plg+/-) mice that had been treated with galardin prior to ovulation, there was a mild (18-20%) reduction in ovulation efficiency. Surprisingly, galardin treatment of plg-deficient (plg-/-) mice only caused an additional 14% reduction in ovulation efficiency as compared to vehicle-treated plg-/- mice. Our data therefore suggest that although MMPs may play a role in degradation of the follicular wall, they may not be obligatory for ovulation. In contrast to previous studies on tissue remodeling during wound healing and placental development, we have demonstrated that there is no obvious functional overlap or synergy between the PA and MMP systems, which has previously been thought to be essential for the ovulatory process. © 2006 Elsevier Inc. All rights reserved.-
dc.languageeng-
dc.relation.ispartofDevelopmental Biology-
dc.subjectMice-
dc.subjectMatrix metalloproteinases-
dc.subjectOvulation-
dc.subjectPlasminogen activators-
dc.titleSuccessful ovulation in plasminogen-deficient mice treated with the broad-spectrum matrix metalloproteinase inhibitor galardin-
dc.typeArticle-
dc.description.natureLink_to_OA_fulltext-
dc.identifier.doi10.1016/j.ydbio.2006.03.046-
dc.identifier.pmid16712832-
dc.identifier.scopuseid_2-s2.0-33745253420-
dc.identifier.volume295-
dc.identifier.issue2-
dc.identifier.spage615-
dc.identifier.epage622-
dc.identifier.isiWOS:000239127700013-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats